These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28425871)

  • 1. The Journey of the Non-Vascular Relief for Migraine: From 'Triptans' To 'Ditans'.
    Xavier AS; Lakshmanan M; Gunaseelan V
    Curr Clin Pharmacol; 2017; 12(1):36-40. PubMed ID: 28425871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the 5-HT
    Huang PC; Yang FC; Chang CM; Yang CP
    Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted 5-HT
    Vila-Pueyo M
    Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
    Raffaelli B; Israel H; Neeb L; Reuter U
    Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profiling lasmiditan as a treatment option for migraine.
    Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
    [No Abstract]   [Full Text] [Related]  

  • 6. Lasmiditan for the treatment of migraine.
    Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecule of the month. Lasmiditan hydrochloride.
    Drug News Perspect; 2010 Sep; 23(7):455. PubMed ID: 20862397
    [No Abstract]   [Full Text] [Related]  

  • 9. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lasmiditan Is a New Option for Acute Migraine Treatment.
    Blakely KK; Stallworth K
    Nurs Womens Health; 2020 Aug; 24(4):294-299. PubMed ID: 32663443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Medications for the Treatment of Migraine.
    Ceriani CEJ; Wilhour DA; Silberstein SD
    Headache; 2019 Oct; 59(9):1597-1608. PubMed ID: 31559638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathophysiological and pharmacological basis of current drug treatment of migraine headache.
    Reddy DS
    Expert Rev Clin Pharmacol; 2013 May; 6(3):271-88. PubMed ID: 23656340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review.
    Ferrari A; Rustichelli C
    Clin Ther; 2021 Apr; 43(4):654-670. PubMed ID: 33608115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.